Developer docs
API playgroundTry for free, no card

Search company profiles

Constantiam Biosciences

Full company profile

uuid000385o

Namestring
Constantiam Biosciences
Legal namestring
Constantiam Biosciences
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Constantiam Biosciences is a preclinical-stage functional genomics company founded in 2020 and headquartered in Watertown, Massachusetts, with additional offices in Seattle, Boston, and Houston. The company builds and operates four integrated platforms — RareScan, MAVEvidence, Genable, and StratiVar — that combine Deep Mutational Scanning (DMS) assays with Bayesian generative modeling and probabilistic machine learning to classify genetic variants of uncertain significance (VUS), generate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for clinical trials. Its primary customers are pharmaceutical companies, diagnostics firms, and clinical genetics laboratories that need scalable functional evidence to support variant interpretation, drug discovery, and trial enrollment; the company also maintains a discovery-stage internal therapeutic pipeline led by CB-001 in lysosomal storage disorders, anchored by a June 2026 strategic collaboration with Cincinnati Children's Hospital Medical Center for neuronopathic Gaucher disease (Types 2 and 3).

The underlying technology is the integration of massively multiplexed cellular assays with human biobank data, enabling classification of thousands of variants simultaneously rather than one at a time. MAVEvidence reportedly contains 476,000+ pieces of evidence across 327,500+ genetic variants, and the company cites peer-validated outcomes including 49% of observed VUS being reclassifiable and 69% of BRCA1 VUS reclassified through MAVE data integration. The platform suite is positioned to support ACMG/AMP variant classification frameworks, regulatory submissions, and clinical trial design.

Constantiam's revenue model rests on three pillars: (1) non-dilutive U.S. federal SBIR grants, including a $2.05M Phase II award from NHGRI and a $485K Phase I award from the National Institute on Aging, totaling approximately $2.535M to date; (2) B2B platform services and data licensing to pharma and diagnostics clients, supported by data licensing deals such as the September 2025 OHSU agreement; and (3) an emerging therapeutic pipeline with potential licensing economics, currently supported by a seed fundraising round. The company employs 1–10 people, generates no publicly disclosed commercial revenue, distributes through direct enterprise sales and content marketing, and is led by co-founders Nicholas Schafer (CEO), Daniel Goldman (CSO), and Norman Ong (CCO) alongside a scientific advisory bench drawn from the Broad Institute, Stanford, and the University of Pittsburgh.

Short descriptiontext

Constantiam Biosciences is a preclinical functional genomics company that uses Deep Mutational Scanning combined with Bayesian generative modeling to resolve variants of uncertain significance, serving pharmaceutical, diagnostics, and clinical genetics laboratory customers across four integrated platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
functional genomics platforms, genetic variant analysis, deep mutational scanning, clinical variant interpretation, drug target discovery
Industry4 codes
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Functional Genomics Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Government Grants (SBIR)
TypeSubscription Recurring
Description

Small Business Innovation Research (SBIR) grants from U.S. federal agencies including NHGRI ($2.05M Phase II) and NIA ($485,000 Phase I) supporting platform development and early-stage research.

prnewswire.com
2Platform Services
TypeSubscription Recurring
Description

Functional genomics platform services for pharma and diagnostics companies, including variant analysis, patient stratification, and drug target discovery.

constantiambio.com
3Seed Funding
TypeLicensing Royalties
Description

Company is raising a seed round to advance pipeline through biomarker-driven development toward IND-enabling studies and First-in-Human trials.

constantiambio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details3 tiers
1Silver Pack
ModelSubscriptionBilling cadenceMonthly
Notes

$30.00 per month - template pricing page

constantiambio.com
2Gold Pack
ModelSubscriptionBilling cadenceMonthly
Notes

$50.00 per month - template pricing page

constantiambio.com
3Platinum Pack
ModelSubscriptionBilling cadenceMonthly
Notes

$70.00 per month - template pricing page

constantiambio.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1RareScan™
Description

Patient expansion platform using Deep Mutational Scanning (DMS) to classify variants of uncertain significance (VUS) and predict drug responses, improving patient access to treatments and clinical trial stratification for rare diseases.

constantiambio.com
+3 more records
Core offering1 text field

Constantiam Biosciences operates four functional genomics platforms (RareScan, MAVEvidence, Genable, and StratiVar) that integrate massively multiplexed Deep Mutational Scanning experiments with human biobank data and probabilistic machine learning to classify variants of uncertain significance (VUS), curate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for rare disease clinical trials. The company also advances a preclinical therapeutic pipeline (CB-001) targeting lysosomal storage disorders including neuronopathic Gaucher disease Types 2 and 3.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 49% of VUS observed by clinical laboratories could be reclassified through MAVE integration
+2 more records
Product overview1 text field

Constantiam Biosciences offers a suite of four integrated functional genomics platforms—RareScan, MAVEvidence®, Genable, and StratiVar—that work together to classify genetic variants, support clinical decision-making, and accelerate precision medicine. RareScan uses Deep Mutational Scanning to classify variants of uncertain significance and predict drug responses for rare disease patients. MAVEvidence® serves as the functional evidence database, curating and presenting evidence from high-throughput variant studies for the clinical genetics community. Genable enables drug target discovery and prioritization through massively-multiplexed experiments and machine learning. StratiVar supports patient stratification for clinical trials by assessing therapeutic susceptibility across protein variants. The company also develops CB-01, a discovery-stage therapeutic program for lysosomal storage disorders.

Product and service1 record
1RareScan
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-18
Description

Strategic collaboration through exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3). Combines Cincinnati Children's validated preclinical data with Constantiam's RareScan functional genomics platform to match therapeutic candidates to responsive patient genotypes across hundreds of GBA1 mutations.

2Oregon Health & Science University (OHSU)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-09-22
Description

License agreement with OHSU to access data from Dr. Brian O'Roak's laboratory, supporting variant interpretation capabilities.

constantiambio.com
Strategic tierSupportingTypeTechnology or Integration
Description

Dr. Nicholas Schafer presented MAVEvidence platform for clinical variant interpretation to consortium members, discussing data flow, infrastructure, and considerations for data collection and harmonization.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company that combines high-throughput wet-lab biology with machine learning for target identification and drug development. Highly comparable to Constantiam in marrying functional genomics experimentation with ML to accelerate precision-medicine discovery, though at significantly larger scale.

TypeDirect peer
Description

Functional genomics company using variant-function maps and high-throughput biology to discover precision medicines for genetic diseases. Closely comparable to Constantiam in combining functional genomics with rare-disease therapeutic focus and a variant-interpretation angle.

TypeDirect peer
Description

Machine-learning-driven drug discovery company using high-throughput cellular biology and functional genomics data. Directly comparable in applying ML to large-scale biological experiments for target discovery and patient stratification, though at substantially greater scale and capital base.

TypeDirect peer
Description

AI-focused company developing genetic medicines by predicting variant effects and identifying oligonucleotide-based therapies. Comparable to Constantiam in using computational/ML approaches to interpret genetic variation and develop rare-disease therapeutics.

TypeBroad incumbent
Description

Established clinical genomics platform using AI to analyze complex genomic and radiomic data for hospitals and clinical labs. Comparable to Constantiam's MAVEvidence platform in serving clinical genetics labs for variant interpretation, but at much larger scale as a publicly traded incumbent.

TypeBroad incumbent
Description

AI-driven clinical genomics interpretation platform for hereditary disease variant classification, now part of GeneDx. Directly comparable to Constantiam's MAVEvidence platform in supporting clinical variant interpretation workflows for hospitals and labs.

TypeDirect peer
Description

Clinical genetics diagnostics company focused on rare-disease variant interpretation and whole-genome sequencing. Comparable to Constantiam in emphasizing functional evidence and clinical-grade variant classification for rare-disease diagnostics.

TypeEmerging player
Description

Functional genomics company focused on regulatory non-coding RNAs for rare disease therapeutics. Comparable to Constantiam in leveraging functional genomics data and computational approaches to drive rare-disease drug discovery at similar stage.

TypeOthers
Description

Non-profit that develops individualized antisense oligonucleotide therapies for ultra-rare disease patients identified through clinical genetic testing. Comparable as a partner/customer ecosystem for functional genomics platforms like RareScan that classify patient-specific VUS for rare disease.

TypeBroad incumbent
Description

Major clinical genomics laboratory serving pediatric rare-disease and hereditary disease diagnostics, with significant variant-interpretation capability following the Fabric Genomics acquisition. Comparable as a large potential customer/competitor for Constantiam's MAVEvidence platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Constantiam Biosciences

Functional Genomics Softwareconstantiambio.com

Constantiam Biosciences is a preclinical functional genomics company that uses Deep Mutational Scanning combined with Bayesian generative modeling to resolve variants of uncertain significance, serving pharmaceutical, diagnostics, and clinical genetics laboratory customers across four integrated platforms.

What Constantiam Biosciences does

Constantiam Biosciences is a preclinical-stage functional genomics company founded in 2020 and headquartered in Watertown, Massachusetts, with additional offices in Seattle, Boston, and Houston. The company builds and operates four integrated platforms — RareScan, MAVEvidence, Genable, and StratiVar — that combine Deep Mutational Scanning (DMS) assays with Bayesian generative modeling and probabilistic machine learning to classify genetic variants of uncertain significance (VUS), generate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for clinical trials. Its primary customers are pharmaceutical companies, diagnostics firms, and clinical genetics laboratories that need scalable functional evidence to support variant interpretation, drug discovery, and trial enrollment; the company also maintains a discovery-stage internal therapeutic pipeline led by CB-001 in lysosomal storage disorders, anchored by a June 2026 strategic collaboration with Cincinnati Children's Hospital Medical Center for neuronopathic Gaucher disease (Types 2 and 3).

The underlying technology is the integration of massively multiplexed cellular assays with human biobank data, enabling classification of thousands of variants simultaneously rather than one at a time. MAVEvidence reportedly contains 476,000+ pieces of evidence across 327,500+ genetic variants, and the company cites peer-validated outcomes including 49% of observed VUS being reclassifiable and 69% of BRCA1 VUS reclassified through MAVE data integration. The platform suite is positioned to support ACMG/AMP variant classification frameworks, regulatory submissions, and clinical trial design.

Constantiam's revenue model rests on three pillars: (1) non-dilutive U.S. federal SBIR grants, including a $2.05M Phase II award from NHGRI and a $485K Phase I award from the National Institute on Aging, totaling approximately $2.535M to date; (2) B2B platform services and data licensing to pharma and diagnostics clients, supported by data licensing deals such as the September 2025 OHSU agreement; and (3) an emerging therapeutic pipeline with potential licensing economics, currently supported by a seed fundraising round. The company employs 1–10 people, generates no publicly disclosed commercial revenue, distributes through direct enterprise sales and content marketing, and is led by co-founders Nicholas Schafer (CEO), Daniel Goldman (CSO), and Norman Ong (CCO) alongside a scientific advisory bench drawn from the Broad Institute, Stanford, and the University of Pittsburgh.

Constantiam Biosciences firmographics

Firmographics
Name
Constantiam Biosciences
Legal name
Constantiam Biosciences
Website
https://constantiambio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Constantiam Biosciences is a preclinical functional genomics company that uses Deep Mutational Scanning combined with Bayesian generative modeling to resolve variants of uncertain significance, serving pharmaceutical, diagnostics, and clinical genetics laboratory customers across four integrated platforms.
Ownership category
akta.pro rank

Constantiam Biosciences industry classification

Industry
Product category
Functional Genomics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Functional genomics platforms
  • Genetic variant analysis
  • Deep mutational scanning
  • Clinical variant interpretation
  • Drug target discovery

Where Constantiam Biosciences is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Constantiam Biosciences business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D

Revenue model

  1. Government Grants (SBIR): Small Business Innovation Research (SBIR) grants from U.S. federal agencies including NHGRI ($2.05M Phase II) and NIA ($485,000 Phase I) supporting platform development and early-stage research.
  2. Platform Services: Functional genomics platform services for pharma and diagnostics companies, including variant analysis, patient stratification, and drug target discovery.
  3. Seed Funding: Company is raising a seed round to advance pipeline through biomarker-driven development toward IND-enabling studies and First-in-Human trials.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlySilver Pack
SubscriptionMonthlyGold Pack
SubscriptionMonthlyPlatinum Pack

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Constantiam Biosciences product offering

Product offering

Core offering

Constantiam Biosciences operates four functional genomics platforms (RareScan, MAVEvidence, Genable, and StratiVar) that integrate massively multiplexed Deep Mutational Scanning experiments with human biobank data and probabilistic machine learning to classify variants of uncertain significance (VUS), curate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for rare disease clinical trials. The company also advances a preclinical therapeutic pipeline (CB-001) targeting lysosomal storage disorders including neuronopathic Gaucher disease Types 2 and 3.

Product overview

Constantiam Biosciences offers a suite of four integrated functional genomics platforms—RareScan, MAVEvidence®, Genable, and StratiVar—that work together to classify genetic variants, support clinical decision-making, and accelerate precision medicine. RareScan uses Deep Mutational Scanning to classify variants of uncertain significance and predict drug responses for rare disease patients. MAVEvidence® serves as the functional evidence database, curating and presenting evidence from high-throughput variant studies for the clinical genetics community. Genable enables drug target discovery and prioritization through massively-multiplexed experiments and machine learning. StratiVar supports patient stratification for clinical trials by assessing therapeutic susceptibility across protein variants. The company also develops CB-01, a discovery-stage therapeutic program for lysosomal storage disorders.

Differentiator

Problem solved

Functional benefit

Brands

  • RareScan™: Patient expansion platform using Deep Mutational Scanning (DMS) to classify variants of uncertain significance (VUS) and predict drug responses, improving patient access to treatments and clinical trial stratification for rare diseases.
  • MAVEvidence®
  • Genable™
  • StratiVar™

Products and services

  • RareScan

Quantifiable outcome

  • 49% of VUS observed by clinical laboratories could be reclassified through MAVE integration
  • +2 more outcomes

Companies that use Constantiam Biosciences

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Constantiam Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Constantiam Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Cincinnati Children's Hospital Medical CentercoreStrategic or Co-development Partner · 18 June 2026Strategic collaboration through exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3). Combines Cincinnati Children's validated preclinical data with Constantiam's RareScan functional genomics platform to match therapeutic candidates to responsive patient genotypes across hundreds of GBA1 mutations.
  • Oregon Health & Science University (OHSU)coreOEM/ Whitelabel/ Licensing Partner · 22 September 2025License agreement with OHSU to access data from Dr. Brian O'Roak's laboratory, supporting variant interpretation capabilities.
  • Variant Interpretation for Cancer Consortium (VICC)supportingTechnology or IntegrationDr. Nicholas Schafer presented MAVEvidence platform for clinical variant interpretation to consortium members, discussing data flow, infrastructure, and considerations for data collection and harmonization.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Constantiam Biosciences competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery company that combines high-throughput wet-lab biology with machine learning for target identification and drug development. Highly comparable to Constantiam in marrying functional genomics experimentation with ML to accelerate precision-medicine discovery, though at significantly larger scale.
  • Maze Therapeutics: Functional genomics company using variant-function maps and high-throughput biology to discover precision medicines for genetic diseases. Closely comparable to Constantiam in combining functional genomics with rare-disease therapeutic focus and a variant-interpretation angle.
  • Insitro: Machine-learning-driven drug discovery company using high-throughput cellular biology and functional genomics data. Directly comparable in applying ML to large-scale biological experiments for target discovery and patient stratification, though at substantially greater scale and capital base.
  • Deep Genomics: AI-focused company developing genetic medicines by predicting variant effects and identifying oligonucleotide-based therapies. Comparable to Constantiam in using computational/ML approaches to interpret genetic variation and develop rare-disease therapeutics.
  • Variantyx: Clinical genetics diagnostics company focused on rare-disease variant interpretation and whole-genome sequencing. Comparable to Constantiam in emphasizing functional evidence and clinical-grade variant classification for rare-disease diagnostics.

Broad incumbents

  • SOPHiA Genetics: Established clinical genomics platform using AI to analyze complex genomic and radiomic data for hospitals and clinical labs. Comparable to Constantiam's MAVEvidence platform in serving clinical genetics labs for variant interpretation, but at much larger scale as a publicly traded incumbent.
  • Fabric Genomics (now GeneDx): AI-driven clinical genomics interpretation platform for hereditary disease variant classification, now part of GeneDx. Directly comparable to Constantiam's MAVEvidence platform in supporting clinical variant interpretation workflows for hospitals and labs.
  • GeneDx: Major clinical genomics laboratory serving pediatric rare-disease and hereditary disease diagnostics, with significant variant-interpretation capability following the Fabric Genomics acquisition. Comparable as a large potential customer/competitor for Constantiam's MAVEvidence platform.

Emerging players

  • CAMP4 Therapeutics: Functional genomics company focused on regulatory non-coding RNAs for rare disease therapeutics. Comparable to Constantiam in leveraging functional genomics data and computational approaches to drive rare-disease drug discovery at similar stage.

Others

  • n-Lorem Foundation: Non-profit that develops individualized antisense oligonucleotide therapies for ultra-rare disease patients identified through clinical genetic testing. Comparable as a partner/customer ecosystem for functional genomics platforms like RareScan that classify patient-specific VUS for rare disease.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Constantiam Biosciences social profiles

Digital presence

Constantiam Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Constantiam Biosciences leadership team

Management profile

Number of profiles

Profiles13 records

Constantiam Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Constantiam Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Constantiam Biosciences

What does Constantiam Biosciences do?

Constantiam Biosciences operates four functional genomics platforms (RareScan, MAVEvidence, Genable, and StratiVar) that integrate massively multiplexed Deep Mutational Scanning experiments with human biobank data and probabilistic machine learning to classify variants of uncertain significance (VUS), curate functional evidence for clinical genetics, prioritize drug targets, and stratify patients for rare disease clinical trials. The company also advances a preclinical therapeutic pipeline (CB-001) targeting lysosomal storage disorders including neuronopathic Gaucher disease Types 2 and 3.

Is Constantiam Biosciences a public or private company?

Constantiam Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Constantiam Biosciences founded?

Constantiam Biosciences was founded in 2020. It employs 1 to 10 people.

Where is Constantiam Biosciences based?

Constantiam Biosciences is headquartered in Watertown, United States, in the North America region.

How does Constantiam Biosciences make money?

Three revenue lines are on record. Government Grants (SBIR) is the primary driver. The others are platform Services and seed Funding.

Who are Constantiam Biosciences's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Maze Therapeutics, Insitro, Deep Genomics and Variantyx. Broad incumbents are SOPHiA Genetics, Fabric Genomics (now GeneDx) and GeneDx. CAMP4 Therapeutics is listed as an emerging player. n-Lorem Foundation is listed as an others.

Does Constantiam Biosciences have an API?

No public API is recorded for Constantiam Biosciences.

What industry is Constantiam Biosciences in?

Constantiam Biosciences's product category is Functional Genomics Software. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceConstantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease TherapiesConstantiam Biosciences and Cincinnati Children's announced a collaboration to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3). The partnership combines Cincinnati Children's preclinical data with Constantiam's RareScan platform to match therapies to patient genotypes. Constantiam is raising a seed round to advance the pipeline toward IND-enabling studies and First-in-Human trials.FinancialContent Business PageConstantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease TherapiesConstantiam Biosciences and Cincinnati Children's announced a strategic collaboration through an exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3). The collaboration combines Cincinnati Children's validated preclinical data with Constantiam's RareScan functional genomics platform to match therapeutic candidates to responsive patient genotypes across hundreds of GBA1 mutations. Constantiam is raising a seed round to advance the pipeline through biomarker-driven development toward IND-enabling studies and First-in-Human trials.GlobeNewswireConstantiam Biosciences and Cincinnati Children’s Collaborate to Accelerate First-in-Class Neuronopathic Gaucher Disease TherapiesConstantiam Biosciences and Cincinnati Children's announced a strategic collaboration through an exclusive option for future licensing rights to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (Types 2 and 3). The collaboration combines Cincinnati Children's validated preclinical data with Constantiam's RareScan functional genomics platform to prospectively match therapeutic candidates to responsive patient genotypes across hundreds of distinct GBA1 mutations. Constantiam is raising a seed round to advance the pipeline through biomarker-driven development toward IND-enabling studies and First-in-Human trials.EIN PresswireConstantiam Biosciences Awarded Business Grant to Advance Genetic Testing for Alzheimer's and DementiaConstantiam Biosciences received a $485,192 Phase I SBIR grant from the National Institute on Aging to develop MAVEvidence, a platform for interpreting genetic variants linked to Alzheimer's and dementia. The project aims to reduce functional data evaluation time by 90% and integrate with the company's Varify platform.FinSMEsConstantiam Biosciences Receives $2.05M Phase II SBIR Grant from NHGRIConstantiam Biosciences received a $2.05M Phase II SBIR grant from NHGRI. The company will use the funds to develop its Varify platform for reclassifying variants of uncertain significance at scale. It also added Nicole Persky and Kirk Gosik as directors.PR NewswireConstantiam Biosciences Secures $2.05M Phase II SBIR Grant from NHGRI to Advance Functional Analysis Platform for Variants of Uncertain Significance (VUS)Constantiam Biosciences has secured a $2.05 million Phase II SBIR grant from the U.S. National Human Genome Research Institute (NHGRI) to develop its Varify™ platform for reclassifying Variants of Uncertain Significance. The funding will support the integration of this platform with MAVEvidence™, aiming to enhance the accuracy and efficiency of genetic variant interpretation for drug discovery and patient care.